Audrey Sternberg
Associate Editorial Director at ONCOLOGY journal
Associate Editorial Director | @CancerNetwrk home of the journal ONCOLOGY [email protected]
Articles
-
Sep 29, 2023 |
targetedonc.com | Audrey Sternberg
REGIMENS COMBINING IMMUNOTHERAPY (IO) plus tyrosine kinase inhibitors (TKIs) are now established, preferred choices in the treatment of previously untreated patients with advanced clear cell renal cell carcinoma (ccRCC), unseating earlier single-agent targeted therapies as the standard of care in this space. Multiple FDA-approved regimens mean patients and their care team have options when selecting the right therapy.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 105
- Tweets
- 91
- DMs Open
- No
RT @CancerNetwrk: Dr. Berruti first RCT ADIUVO of adj #mitotane in resected stage I-III #adrenocortical carcinoma (ACC) shows no sig diff i…
RT @CancerNetwrk: @PGrivasMDPhD Ph II TROPHY-U-01 Cohort 3 Sac govitecan (SG) + pembro after platinum in adv #blcsm ORR 34%, >G3 AEs diarrh…
RT @CancerNetwrk: @DanielPetrylak EV-103 Cohort H Ph In/II #enfortumab vedotin cis-ineligible #MIBC X3 neoadjuvant then RC + PLND pCR 36.4%…